Accelerating global innovation to address antibacterial resistance: introducing CARB-X

Nature Reviews Drug Discovery volume 15, pages589–590(2016)Cite this article

Article metrics

Subjects

Abstract

A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public–private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

References

  1. 1

    Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations http://amr-review.org (2016).

  2. 2

    Laxminarayan, R. et al. Antibiotic resistance—the need for global solutions. Lancet Infect. Dis. 13, 1057–1098 (2013).

  3. 3

    Rex, J. H. & Outterson, K. Antibiotic reimbursement in a sales-delinked model: context and a benchmark-based global approach. Lancet Infect. Dis. 16, 500–505 (2016).

  4. 4

    Outterson, K. New business models for sustainable antibiotics. Chatham House http://www.chathamhouse.org/publications/papers/view/197446 (2014).

Download references

Author information

Affiliations

  1. Boston University School of Law, Boston, 02215, Massachusetts, USA

    • Kevin Outterson

  2. Chatham House, London, SW1Y 4LE, UK

    • Kevin Outterson

  3. AstraZeneca Pharmaceuticals, Waltham, 02451, Massachusetts, USA

    • John H. Rex

  4. University of Texas Medical School–Houston, Houston, 77225, Texas, USA

    • John H. Rex

  5. Wellcome Trust, London, NW1 2BE, UK

    • Tim Jinks

  6. AMR Centre, Alderley Park, SK10 4TG, Manchester, UK

    • Peter Jackson

  7. Mass Bio, Cambridge, 02139, Massachusetts, USA

    • John Hallinan

  8. California Life Sciences Institute, South San Francisco, 94080, California, USA

    • Steve Karp

  9. Broad Institute, Cambridge, 02142, Massachusetts, USA

    • Deborah T. Hung

  10. Harvard Medical School, Boston, 02215, Massachusetts, USA

    • Deborah T. Hung

  11. Massachusetts General Hospital, Boston, 02114, Massachusetts, USA

    • Deborah T. Hung

  12. National Institute of Allergy and Infectious Diseases, Bethesda, 20892, Maryland, USA

    • Francois Franceschi
    • , Dennis M. Dixon
    • , Michael G. Kurilla
    •  & Rosemarie Aurigemma

  13. Biomedical Advanced Research and Development Authority, 20201, Washington, DC, USA

    • Tyler Merkeley
    • , Christopher Houchens
    •  & Joseph Larsen

Authors

  1. Search for Kevin Outterson in:

  2. Search for John H. Rex in:

  3. Search for Tim Jinks in:

  4. Search for Peter Jackson in:

  5. Search for John Hallinan in:

  6. Search for Steve Karp in:

  7. Search for Deborah T. Hung in:

  8. Search for Francois Franceschi in:

  9. Search for Tyler Merkeley in:

  10. Search for Christopher Houchens in:

  11. Search for Dennis M. Dixon in:

  12. Search for Michael G. Kurilla in:

  13. Search for Rosemarie Aurigemma in:

  14. Search for Joseph Larsen in:

Corresponding author

Correspondence to Kevin Outterson.

Ethics declarations

Competing interests

J.H.R. is an employee and shareholder of AstraZeneca Pharmaceuticals, non-executive board member, senior advisor and shareholder of F2G Pharmaceuticals; non-executive board member of Adenium Biotech ApS; Expert-in-residence, Wellcome Trust; and operating partner and consultant, Advent Life Sciences. P.J. is executive director of AMR Centre Ltd; non-executive director of Redx Pharma Plc; non-executive director of Yprotech Ltd; non-executive director of Biovictrix Therapeutics Ltd; and owner and director of Intelia Consulting.

Related links

Related links

FURTHER INFORMATION

CARB-X

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Outterson, K., Rex, J., Jinks, T. et al. Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov 15, 589–590 (2016) doi:10.1038/nrd.2016.155

Download citation

Further reading